Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis | Infectious Diseases of Poverty | Full Text
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Tocilizumab in the treatment of adult rheumatoid arthritis | Immunotherapy
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Frontiers | Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19 | Pharmacology
Figure 1 | Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Tocilizumab Raises GI Risks in Rheumatoid Arthritis | MedPage Today
Treatment of Rheumatoid Arthritis with Biological Agents | IntechOpen
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
About ACTEMRA® (tocilizumab) Treatment Info for Healthcare Professionals
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? | Medicine
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy | Nature Reviews Immunology
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Actemra Shortage: What to Do If You Can't Access Tocilizumab
